Trial Profile
AMC 061: A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Antiretrovirals
- Indications Haematological malignancies; HIV infections; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 27 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Dec 2012 Planned end date changed from 1 Dec 2012 to 1 May 2013 as reported by ClinicalTrials.gov.